PodParley PodParley
PodParley
Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study episode artwork

EPISODE · Sep 28, 2024 · 6 MIN

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study

from Medical Digest & Congress Report · host Medical Congress News

Professor Peter Schmid presented the overall survival results from the phase 3 KEYNOTE-522 study at ESMO 2024 Congress. Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC. Video: https://medicaldigest.org/scientific-contents/interview:neoadjuvant-pembrolizumab-or-placebo-plus-chemotherapy-followed-adjuvant-pembrolizumab-or-placebo-high-risk-early-stage-tnbc-overall-survival-results-phase-3-keynote-522-study

Episode metadata supplied by the publisher feed · Published Sep 28, 2024

Embed this episode

Ready to play

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study

0:00 6:25

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 6 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on September 28, 2024.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!